Dr John Unitt

John joined Sygnature in August 2011 from AstraZeneca to establish and lead the Bioscience group. Under his leadership, the Bioscience department played a key part in Sygnature’s growth. He is now the Therapeutic Area Lead for inflammation and immunology and works to develop Sygnature’s partnerships with customers, investors and project teams in this area. John is a highly experienced pharmaceutical bioscientist and has worked in a broad range of drug discovery phases from biological target identification and validation, hit identification from multiple sources (e.g. HTS, natural products, fragment-based), novel assay development, hit-to-lead and lead optimisation. He worked for AstraZeneca R&D Charnwood for over 20 years and was instrumental in its development and success of hit-to-lead.

John has a BSc (Hons) in Biochemistry from the University of Bristol, a PhD on Cardiac Bioenergetics from the University of Leeds and he undertook post-doctoral research on biological NMR at the University of Oxford.